Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28994413 | 1.00 | SLC22A6 (0.33) | SLC22A6 | |
| SCHEMBL28787923 | 0.86 | TDP1 (0.40) | — | |
| SCHEMBL17542033 | 0.77 | CA2 (0.33) | — | |
| SCHEMBL17542096 | 0.77 | CA2 (0.33) | — | |
| SCHEMBL23442993 | 0.77 | — | — | |
| Sulfuric Acid SCHEMBL19285797 | 0.77 | TP53 (0.33) | — | |
| SCHEMBL17542032 | 0.77 | CA2 (0.33) | — | |
| SCHEMBL10708540 | 0.77 | SLC22A6 (0.43) | SLC22A6 | |
| SCHEMBL28669334 | 0.76 | SLC22A6 (0.36) | SLC22A6 | |
| SCHEMBL28834692 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760736-B2 | Processes and intermediates for preparing MCL1 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11760736-B2 | Processes and intermediates for preparing MCL1 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230013713-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11760736-B2 | Processes and intermediates for preparing MCL1 inhibitors | MCL1, BAK1, BCL3 | SLC22A6 4053/4885 |
| US-20230013713-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS | MCL1, BAK1, BCL3 | SLC22A6 4053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.